MEZIXUS Trademark

Trademark Overview


On Thursday, May 13, 2021, a trademark application was filed for MEZIXUS with the United States Patent and Trademark Office. The USPTO has given the MEZIXUS trademark a serial number of 90710128. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Tuesday, October 29, 2024. This trademark is owned by Celgene Corporation. The MEZIXUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
mezixus

General Information


Serial Number90710128
Word MarkMEZIXUS
Filing DateThursday, May 13, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateTuesday, October 29, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 6, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical and biological preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders, and monoclonal antibodies for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 29, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Thursday, August 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, January 20, 2022ASSIGNED TO EXAMINER
Thursday, January 27, 2022NON-FINAL ACTION WRITTEN
Thursday, January 27, 2022NON-FINAL ACTION E-MAILED
Thursday, January 27, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 18, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 18, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 18, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 17, 2021NEW APPLICATION ENTERED
Friday, July 29, 2022EXAMINER'S AMENDMENT ENTERED
Friday, July 29, 2022EXAMINERS AMENDMENT -WRITTEN
Friday, July 29, 2022EXAMINERS AMENDMENT E-MAILED
Friday, July 29, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Saturday, July 30, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 17, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, September 6, 2022PUBLISHED FOR OPPOSITION
Tuesday, September 6, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 1, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, April 24, 2023SOU TEAS EXTENSION RECEIVED
Monday, April 24, 2023SOU EXTENSION 1 FILED
Monday, April 24, 2023SOU EXTENSION 1 GRANTED
Wednesday, April 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 12, 2023SOU TEAS EXTENSION RECEIVED
Thursday, October 12, 2023SOU EXTENSION 2 FILED
Thursday, October 12, 2023SOU EXTENSION 2 GRANTED
Saturday, October 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 5, 2024SOU EXTENSION 3 GRANTED
Friday, April 5, 2024SOU EXTENSION 3 FILED
Friday, April 5, 2024SOU TEAS EXTENSION RECEIVED
Saturday, April 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 29, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, October 29, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 29, 2024SOU EXTENSION 4 GRANTED
Tuesday, October 29, 2024SOU EXTENSION 4 FILED